Monthly information on share capital and company voting rights
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) ha pubblicato il suo rapporto mensile sul capitale azionario e sui diritti di voto al 31 marzo 2025. L'azienda ha riportato un totale di 100.290.078 azioni nella sua struttura di capitale, con 89.046.759 diritti di voto totali. Questa comunicazione è conforme all'Articolo 223-16 del Regolamento Generale dell'autorità dei mercati finanziari francese per le aziende quotate su Euronext Growth.
Cellectis (CLLS) ha publicado su informe mensual sobre el capital social y los derechos de voto a 31 de marzo de 2025. La empresa reportó un total de 100.290.078 acciones en su estructura de capital, con 89.046.759 derechos de voto totales. Esta divulgación cumple con el Artículo 223-16 del Reglamento General de la autoridad de los mercados financieros franceses para las empresas cotizadas en Euronext Growth.
Cellectis (CLLS)는 2025년 3월 31일 기준으로 월간 주식 자본 및 의결권 보고서를 발표했습니다. 회사는 자본 구조에서 총 100,290,078주를 보고했으며, 89,046,759개의 총 의결권을 보유하고 있습니다. 이 공시는 Euronext Growth에 상장된 회사에 대한 프랑스 금융 시장 당국의 일반 규정 제223-16조를 준수합니다.
Cellectis (CLLS) a publié son rapport mensuel sur le capital social et les droits de vote au 31 mars 2025. L'entreprise a déclaré un total de 100.290.078 actions dans sa structure de capital, avec 89.046.759 droits de vote totaux. Cette divulgation est conforme à l'Article 223-16 du Règlement Général de l'autorité des marchés financiers français pour les entreprises cotées sur Euronext Growth.
Cellectis (CLLS) hat seinen monatlichen Bericht über das Aktienkapital und die Stimmrechte zum 31. März 2025 veröffentlicht. Das Unternehmen berichtete von insgesamt 100.290.078 Aktien in seiner Kapitalstruktur, mit 89.046.759 insgesamt Stimmrechten. Diese Offenlegung entspricht Artikel 223-16 der Allgemeinen Verordnung der französischen Finanzmarktaufsichtsbehörde für Unternehmen, die an Euronext Growth notiert sind.
- None.
- None.
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, April 07, 2025 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 03/31/2025 | 100,290,078 | 89,046,759 |
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
What is the total number of Cellectis (CLLS) shares as of March 31, 2025?
How many voting rights does Cellectis (CLLS) have as of March 2025?
What is the difference between Cellectis (CLLS) total shares and voting rights in March 2025?
On which exchange is Cellectis (CLLS) stock listed according to the March 2025 report?
